This is the latest version of this eprint.
Hill, R., Madureira, P.A., Ferreira, B. et al. (12 more authors) (2023) Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT. Nature Communications, 14 (1). 4341. ISSN 2041-1723
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © The Author(s) 2023. Open Access: This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > Department of Infection, Immunity and Cardiovascular Disease |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 25 Jul 2023 14:21 |
Last Modified: | 25 Jul 2023 14:21 |
Status: | Published |
Publisher: | Springer Science and Business Media LLC |
Refereed: | Yes |
Identification Number: | 10.1038/s41467-023-40050-1 |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:201889 |
Available Versions of this Item
-
TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT. (deposited 01 Feb 2017 11:44)
- Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT. (deposited 25 Jul 2023 14:21) [Currently Displayed]